NASDAQ: DRMA · Biotechnology
Over the past week, Dermata Therapeutics (DRMA) drew about 36 mentions across Reddit, X and news, and the read is an Adanos Buy. The crowd averages 58% bullish but is far apart: News runs 80% bullish while X sits at just 43%. Wall Street is more constructive, with 1 of 1 analysts rating DRMA a buy.
“DRMA is trending because a major technical breakout is underway with a fundamental shift approaching, fueled by an impending revenue-generating product release.”Adanos /explain
Wall Street’s 100% buy share sits next to a crowd that ranges from X at 43% to News at 80%. No other tracker puts the two side by side.
Across 1 analysts the consensus is a Strong Buy: 1 buy call against 0 sell, with an average 12-month price target of $4.00.
The Adanos signal blends each source’s bullish ratio, source breadth, buzz intensity and 3-day momentum. This week bullish sits above the neutral line, momentum is improving and the 3 sources disagree sharply, so the read is a Buy.
Analysts sit 42 points above the crowd average of 58%, the professionals are more constructive than retail. The split is inside the crowd: News reads 80% bullish while X sits at 43%, a 37-point spread that single-source trackers miss.
Over the 30-day window, Dermata Therapeutics (DRMA) buzz held subdued around 27.4 while the price drifted up 9.8% across the period. The chart tracks how social and news attention moved against end-of-day price. Average daily trading volume across the displayed trading days is 2M shares. Updated Aug 15, 2026. Over the last 7 trading days, DRMA gained 31.5%. Buzz activity in the recent week averaged 28.4 and was relatively stable, swinging between 21.2 and 38.6. Recent volume is running above the 30-day average, suggesting heightened trading interest. Daily crowd sentiment leaned bullish on 5 of the 7 days with directional mentions, shown as the green, grey and red breakdown bars below the chart.
Signal metrics use the latest 7 days; contributor and breadth context uses the 30-day chart window.
No Polymarket data for this stock this week.
Query sentiment for DRMA and 2000+ stocks from your terminal. Filter by source, timeframe and signal strength.
View CLIEmbed live DRMA sentiment on your own site with drop-in web components.
View WidgetsThis week’s sentiment from Adanos, with fundamentals and analyst consensus. A quick-reference snapshot for Aug 15, 2026.
| Adanos signal | Buy |
|---|---|
| Analyst consensus | Strong Buy (1 / 0 / 0) |
| Crowd bullish (7d) | 58% |
| Avg price target | $4.00 |
| Most bullish source | News, 80% |
| Most bearish source | X, 43% |
| Sentiment spread | 37 pts |
| Mentions (7d) | 36 |
| Market cap | $5.9M |
| EPS · Beta | -$3.81 · 0.7 |
| Industry | Biotechnology |
Based on aggregated sentiment from Reddit, X and News sources, Dermata Therapeutics (DRMA) currently carries an Adanos buy signal with 93/100 conviction. The current cross-source average reads 58% bullish across 3 active sources. Those sources contribute 36 tracked mentions over the last 7 days. This is a sentiment-based reading, not financial advice.
Reddit discussion around Dermata Therapeutics (DRMA) is fairly quiet with 10 mentions over the last 7 days; the 30-day context spans 4 tracked subreddits. The 7-day tone is 50% bullish; 3-day activity momentum is stable, suggesting steady attention.
The crowd reads bullish on Dermata Therapeutics (DRMA), averaging 58% bullish across 3 tracked sources over the last 7 days. The two ends of the range are News at 80% bullish and X at 43%, a 37-point spread. On the professional side, 1 of 1 analysts rate DRMA a buy.
Of the 1 analyst covering Dermata Therapeutics (DRMA), 1 rate it a buy, 0 a hold and 0 a sell, for a strong buy consensus. The average price target is $4.00. That puts the street ahead of the crowd, which averages 58% bullish.
Dermata Therapeutics (DRMA)'s cross-source average is bullish at 58% bullish. Source readings are split: 1 source leans bullish, 1 source leans bearish and 1 source sits at 50% bullish. Reddit reads 50% bullish, News reads 80% bullish and x coverage is the most negative at 43% bullish. The combined signal points to broad buy-side pressure with 93/100 conviction.
The cross-source average is bullish for Dermata Therapeutics (DRMA) at 58% bullish. Source readings are split: 1 source leans bullish, 1 source leans bearish and 1 source sits at 50% bullish. The most bearish reading is x at 43% bullish. 3-day activity momentum is rising across X and News. The buy signal carries 93/100 conviction.
X is the dominant discussion channel with 21 mentions (58% of total volume). Reddit contributes 10 mentions and News contributes 5 mentions. The cross-source average is bullish at 58% bullish, while x and news show rising 3-day activity. Source readings are split: 1 source leans bullish, 1 source leans bearish and 1 source sits at 50% bullish.
The Adanos signal blends bullish ratio, buzz score, source breadth and 3-day activity momentum into a single buy/sell reading. DRMA's buy signal at 93/100 conviction reflects a bullish cross-source average at 58% bullish. Source readings are split: 1 source leans bullish, 1 source leans bearish and 1 source sits at 50% bullish. It is a research shortcut, not financial advice.
The DRMA sentiment page is regenerated from the latest 7-day tracking window at each build. Data reflects the most recent Reddit posts, tweets and news articles available in the current publishing cycle.
Peers are ranked first by matching the Buy signal, then by the closest bullish ratio. Discussion activity breaks any remaining ties.
Every data point on this page comes from the Adanos sentiment APIs. Get a free API key and start querying Reddit, X, News and Polymarket sentiment programmatically.
Get Free API Key